Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 48.54B P/E 21.46 EPS this Y - Ern Qtrly Grth -11.00%
Income 325.47B Forward P/E - EPS next Y - 50D Avg Chg 3.00%
Sales 1.11T PEG - EPS past 5Y - 200D Avg Chg 12.00%
Dividend 528.00% Price/Book 0.03 EPS next 5Y - 52W High Chg -5.00%
Recommedations - Quick Ratio 3.68 Shares Outstanding 3.29B 52W Low Chg 33.00%
Insider Own - ROA 14.44% Shares Float 639.37M Beta 0.48
Inst Own 0.01% ROE 21.34% Shares Shorted/Prior -/- Price 14.59
Gross Margin 62.81% Profit Margin 29.29% Avg. Volume 213,117 Target Price -
Oper. Margin 44.34% Earnings Date - Volume 338,738 Change -3.70%
About CHUGAI PHARMACEUTICAL CO UNSPN

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.